Edgewise Therapeutics, Inc., , a leading muscle disease biopharmaceutical company, today announced that the U.S. Food & Drug Administration has granted EDG-5506 Orphan Drug Designation for the.
Local News: September 6th, 2023 silvercityradio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from silvercityradio.com Daily Mail and Mail on Sunday newspapers.
By Chris Wack Edgewise Therapeutics shares were up 10% at $7.56 after the company said it saw positive 12-month topline results from its ongoing study.